3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Arterial Hypertension
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Number of death from any cause
- Last Updated
- 8 years ago
Overview
Brief Summary
Pulmonary hypertension is a rare and severe disease, affecting a young population. Survival is very poor and has been closely related to right ventricular dysfunction. Current prognostic equations rely mostly on right heart catheterization data. The identification of simple echocardiographic prognostic factor is urgently needed. It could help identifying with a non invasive method, high risk patients who could benefit from an intensive specific therapy. 3D right ventricular imaging is a new echocardiographic tool which provides RV volumic analysis, RV ejection fraction, overcoming the classical limits of 2D ultrasound.
The aim of this study is to validate a new software for 3D analysis of the right ventricle and assess its prognostic role in pulmonary hypertension.
To do so, the investigators will realize a prospective monocentric longitudinal cohort study, including 100 pulmonary hypertension patients. Echocardiographic data will be collected at baseline and after 6 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \> 18 years old
- •Pulmonary hypertension diagnosed by right heart catheterization
- •Informed consent obtained
- •Affiliation to the French national health insurance
Exclusion Criteria
- •Associated significant left heart disease
- •Sub-optimal acoustic windows
- •Patient unable to attend follow-up visits
Outcomes
Primary Outcomes
Number of death from any cause
Time Frame: Baseline to 24 months
Description of the number of death during the study
Secondary Outcomes
- Number of Hospitalisation(Baseline to 24 months)
- 3D right ventricular imaging echocardiographic(Baseline and 6 months)